{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T13:16:50Z","timestamp":1648732610015},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.clinthera.2016.11.021","type":"journal-article","created":{"date-parts":[[2016,12,20]],"date-time":"2016-12-20T23:17:35Z","timestamp":1482275855000},"page":"66-74","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Health Status of Patients with Moderate to Severe COPD after Treatment with Nebulized Arformoterol Tartrate or Placebo for 1 Year"],"prefix":"10.1016","volume":"39","author":[{"given":"James F.","family":"Donohue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaidyanathan","family":"Ganapathy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vamsi","family":"Bollu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Stensland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren M.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2016.11.021_bib1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD. http:\/\/goldcopd.org\/global-strategy-diagnosis-management-prevention-copd-2016\/. Accessed June 27, 2016."},{"key":"10.1016\/j.clinthera.2016.11.021_bib2","series-title":"Mortality in the United States, 2013 (NCHS data brief No. 178)","author":"Kochanek","year":"2014"},{"key":"10.1016\/j.clinthera.2016.11.021_bib3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cpt.249","article-title":"A model-based longitudinal meta-analysis of FEV1 in randomized COPD trials","volume":"99","author":"Korell","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2016.11.021_bib4","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2147\/COPD.S32675","article-title":"Beyond FEV(1) in COPD: a review of patient-reported outcomes and their measurement","volume":"7","author":"Jones","year":"2012","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.clinthera.2016.11.021_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1477-7525-1-13","article-title":"Development, validity and responsiveness of the Clinical COPD Questionnaire","volume":"1","author":"van der Molen","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.clinthera.2016.11.021_bib6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1465-9921-12-40","article-title":"Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review","volume":"12","author":"Westwood","year":"2011","journal-title":"Respir Res"},{"key":"10.1016\/j.clinthera.2016.11.021_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-2466-12-20","article-title":"Assessing health status in COPD. A head-to-head comparison between the COPD assessment test (CAT) and the clinical COPD questionnaire (CCQ)","volume":"12","author":"Tsiligianni","year":"2012","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.clinthera.2016.11.021_bib8","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3109\/15412555.2013.773302","article-title":"Perceptions and attitudes toward the use of nebulized therapy for COPD: patient and caregiver perspectives","volume":"10","author":"Sharafkhaneh","year":"2013","journal-title":"COPD"},{"key":"10.1016\/j.clinthera.2016.11.021_bib9","first-page":"23","article-title":"Considerations for managing chronic obstructive pulmonary disease in the elderly","volume":"9","author":"Taffet","year":"2014","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.clinthera.2016.11.021_bib10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3109\/15412555.2011.630047","article-title":"The role of nebulized therapy in the management of COPD: evidence and recommendations","volume":"9","author":"Dhand","year":"2012","journal-title":"COPD"},{"key":"10.1016\/j.clinthera.2016.11.021_bib11","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.clinthera.2007.02.009","article-title":"Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial","volume":"29","author":"Baumgartner","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2016.11.021_bib12","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1378\/chest.14-0117","article-title":"One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD","volume":"146","author":"Donohue","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2016.11.021_bib13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1465-9921-7-62","article-title":"Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire","volume":"7","author":"Kocks","year":"2006","journal-title":"Respir Res"},{"key":"10.1016\/j.clinthera.2016.11.021_bib14","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1136\/thoraxjnl-2013-204119","article-title":"The Clinical COPD Questionnaire: response to pulmonary rehabilitation and minimal clinically important difference","volume":"69","author":"Kon","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.clinthera.2016.11.021_bib15","unstructured":"World Health Organization Collaborating Centre for Drug Statistics Methodology. Anatomoical therapeutic chemical (ATC) classification index with defined daily doses (DDD). http:\/\/www.whocc.no\/atc_ddd_index\/. Accessed September 23, 2016."},{"key":"10.1016\/j.clinthera.2016.11.021_bib16","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1183\/09031936.00099306","article-title":"Outcomes for COPD pharmacological trials: from lung function to biomarkers","volume":"31","author":"Cazzola","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.clinthera.2016.11.021_bib17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4104\/pcrj.2012.00065","article-title":"Patient-centred assessment of COPD in primary care: experience from a cross-sectional study of health-related quality of life in Europe","volume":"21","author":"Jones","year":"2012","journal-title":"Prim Care Respir J"},{"key":"10.1016\/j.clinthera.2016.11.021_bib18","first-page":"1397","article-title":"The concept of control of COPD in clinical practice","volume":"9","author":"Soler-Cataluna","year":"2014","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.clinthera.2016.11.021_bib19","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1465-9921-14-64","article-title":"Efficacy and safety of AZD3199 vs formoterol in COPD: a randomized, double-blind study","volume":"14","author":"Kuna","year":"2013","journal-title":"Respir Res"},{"key":"10.1016\/j.clinthera.2016.11.021_bib20","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.2147\/COPD.S83071","article-title":"A real-world evaluation of indacaterol and other bronchodilators in COPD: the INFLOW study","volume":"10","author":"Juvelekian","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.clinthera.2016.11.021_bib21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.15326\/jcopdf.3.2.2015.0152","article-title":"Relationship between FEV1 and patient-reported outcomes changes: results of a metaanalysis of randomized trials in stable COPD","volume":"3","author":"de la Loge","year":"2016","journal-title":"Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.clinthera.2016.11.021_bib22","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12931-016-0356-1","article-title":"The association of lung function and St. George\u05f3s Respiratory Questionnaire with exacerbations in COPD: a systematic literature review and regression analysis","volume":"17","author":"Martin","year":"2016","journal-title":"Respir Res"},{"key":"10.1016\/j.clinthera.2016.11.021_bib23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1477-7525-11-85","article-title":"Utility of brief questionnaires of health-related quality of life (Airways Questionnaire 20 and Clinical COPD Questionnaire) to predict exacerbations in patients with asthma and COPD","volume":"11","author":"Blanco-Aparicio","year":"2013","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.clinthera.2016.11.021_bib24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1378\/chest.14-2449","article-title":"Differential effect of Modified Medical Research Council dyspnea, COPD Assessment Test, and Clinical COPD Questionnaire for symptoms evaluation within the new GOLD staging and mortality in COPD","volume":"148","author":"Casanova","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2016.11.021_bib25","first-page":"273","article-title":"Day-to-day measurement of patient-reported outcomes in exacerbations of chronic obstructive pulmonary disease","volume":"8","author":"Kocks","year":"2013","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.clinthera.2016.11.021_bib26","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.2147\/COPD.S91163","article-title":"The chronic obstructive pulmonary disease assessment test improves the predictive value of previous exacerbations for poor outcomes in COPD","volume":"10","author":"Miravitlles","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.clinthera.2016.11.021_bib27","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2147\/COPD.S38119","article-title":"Clinical COPD Questionnaire score (CCQ) and mortality","volume":"7","author":"Sundh","year":"2012","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.clinthera.2016.11.021_bib28","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.rmed.2009.01.001","article-title":"Global assessment of the COPD patient: time to look beyond FEV1?","volume":"103","author":"Papaioannou","year":"2009","journal-title":"Respir Med"},{"key":"10.1016\/j.clinthera.2016.11.021_bib29","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1080\/10543400903242795","article-title":"An overview of practical approaches for handling missing data in clinical trials","volume":"19","author":"DeSouza","year":"2009","journal-title":"J Biopharm Stat"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816308888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816308888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T18:53:13Z","timestamp":1536173593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291816308888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0149291816308888"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.11.021","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health Status of Patients with Moderate to Severe COPD after Treatment with Nebulized Arformoterol Tartrate or Placebo for 1 Year","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}